RE:RE:RE:Example of a jv deal
Eoganacht wrote: Conferences are more about educating urologists as to the advantages of our treatment, so that when we are allowed to commercialize there is a ( hopefully eagerly anticipating ) market for our product. Despite all the cynical conspiracy theories being noised about, I believe medical specialists are genuinely looking out for the best interests of their patients - and that entails providing them with the best possible treatment. And if urologists understand that TLD1433 PDT is the best treatment available for BCG unresponsive NMIBC this will translate into having the lion's share of this market and a very healthy stock price.
The practice of medicine (under the pressure of high costs & a growing centralized/managed healthcare system) is becoming more & more evidence-based (i.e. less bending to individual physician preferences), & drug formulary committees have to not only consider a drug or treatment's efficacy & safety, but also have to examine the impact of cost/reimbursement potential in this high cost environment. The above trend should favor our ACT. Drug/supply chain shortages (I.e. BCG) should also lend support for use of our ACT.
If all continues to go well from a data/scientific perspective, getting physician leaders to buy-in to our ACT should be a relatively small hill to climb....just need to continue to get the word out. All imo.